




Management of elderly ulcerative colitis in Japan

Masaaki Higashiyama¹  · Akira Sugita² · Kazutaka Koganei² · Kenji Wanatabe³ · Yoko Yokoyama³ · Motoi Uchino⁴ · Masakazu Nagahori⁵ · Makoto Naganuma⁶ · Shigeki Bamba⁷ · Shingo Kato⁸ · Ken Takeuchi⁹ · Teppei Omori¹⁰ · Tomohisa Takagi¹¹ · Satohiro Matsumoto¹² · Mitsuo Nagasaka¹³ · Shintaro Sagami¹⁴ · Kazuya Kitamura¹⁵ · Takehiko Katsurada¹⁶ · Ken Sugimoto¹⁷ · Noritaka Takatsu¹⁸ · Masayuki Saruta¹⁹ · Toshiyuki Sakurai¹⁹ · Kazuhiro Watanabe²⁰ · Shiro Nakamura³ · Yasuo Suzuki²¹ · Ryota Hokari¹

Received: 29 March 2019 / Accepted: 8 April 2019 / Published online: 20 April 2019
© The Author(s) 2019, corrected publication 2019

Abstract Japan has the largest aging society, where many elderly people have intractable diseases including ulcerative colitis (UC). Along with the increasing total number of UC patients, the number of elderly UC patients has also been increasing and will continue to do so in the future. Although the clinical features and natural history of UC in the elderly have many similarities with UC in the non-elderly population, age-specific concerns including comorbidities, immunological dysfunction, and polypharmacy make the diagnosis and management of elderly UC

challenging compared to UC in non-elderly patients. Based on increasing data related to elderly UC patients from Japan, as well as other countries, we reviewed the epidemiology, clinical course, differential diagnosis, management of comorbidities, surveillance, medical therapy, and surgery of UC in the elderly.

Keywords Ulcerative colitis · Inflammatory bowel disease · Elderly · Management

✉ Masaaki Higashiyama
masaakih@ndmc.ac.jp

¹ Department of Internal Medicine, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan

² Inflammatory Bowel Disease Center, Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan

³ Department of Intestinal Inflammation Research, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan

⁴ Department of Inflammatory Bowel Disease, Division of Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan

⁵ Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan

⁶ Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

⁷ Division of Clinical Nutrition, Shiga University of Medical Science, Otsu, Shiga, Japan

⁸ Department of Gastroenterology and Hepatology, Saitama Medical Center, Saitama Medical University, Saitama, Japan

⁹ Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Sakura Medical Centre, Sakura, Chiba, Japan

¹⁰ Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan

¹¹ Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan

¹² Department of Gastroenterology, Saitama Medical Center, Jichi Medical University, Saitama, Japan

¹³ Department of Gastroenterology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

¹⁴ Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan

¹⁵ Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan

¹⁶ Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan

¹⁷ First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan

¹⁸ Department of Gastroenterology, Fukuoka University Chikushi Hospital, Chikushino, Fukuoka, Japan

¹⁹ Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan

Abbreviations

AEs	Adverse events
CAP	Cytapheresis
CD	Crohn's disease
C.	<i>Clostridioides (Clostridium) difficile</i>
<i>difficile</i>	
CDAD	<i>Clostridium (Clostridioides) difficile</i> -associated diarrhea
CMV	Cytomegalovirus
ECCO	European Crohn's and Colitis organization
HBV	Hepatitis B virus
HZV	Herpes zoster virus
IBD	Inflammatory bowel disease
IPAA	Ileal pouch anal anastomosis
IRA	Ileorectal anastomosis
NSAIDs	Non-steroidal anti-inflammatory drugs
PPIs	Proton pump inhibitors
SCAD	Segmental colitis associated with diverticulosis
SRUS	Solitary rectal ulcer syndrome
TB	Tuberculosis
TNF	Tumor necrosis factor
TPC	Total proctocolectomy with end ileostomy
UC	Ulcerative colitis
5-ASA	5-Aminosalicylic acid
LEUC	Longstanding elderly UC (elderly UC patients who had first diagnosed as having UC at a young age)
EOUC	Elderly-onset UC (elderly UC patients with onset of UC at a late age)
Elderly UC	UC patients including LEUC and EOUC
NEOUC	Non-elderly-onset UC

Introduction

Japan has the largest aging society with an average life span of more than 80 years in 2017 (81.09 years in males and 87.26 years in females) [1], and those who are 65 years or older comprise 27.7% of the society [2]. In this graying society, the elderly population faces many problems including comorbidities, immunological dysfunction, and polypharmacy.

There are many elderly people with intractable diseases including inflammatory bowel disease (IBD), comprising Crohn's disease (CD) and ulcerative colitis (UC), a chronic immunologically mediated disease at the intersection of

complex interactions between genetics, environment, and gut microbiota [3]. While early life events such as birth, breastfeeding, and exposure to antibiotic and later childhood events are considered potential risk factors [4], IBD can present at any age. In Japan, the number of UC patients has been increasing year by year. Estimates based on the issued numbers of certificates of recipients of medical service and certificates of registration in 2013 showed that there are over 160,000 patients with UC (approximately 100 cases per 100,000) [5]. Approximately 10% of newly registered UC patients were 65 years old or more according to a nationwide study [6], suggesting that the number of elderly UC patients has also been increasing and will continue to do so in the future.

Although the clinical features and natural history of elderly UC have many similarities with non-elderly UC, the diagnosis and management of elderly UC patients are challenging compared to non-elderly UC patients owing to age-specific concerns. Considering that elderly UC patients have higher rates of cardiac diseases, infections, malignancies, and UC-related mortalities, elderly UC patients need to be treated more carefully than non-elderly UC patients [7, 8]. There are already some reviews or guidelines for IBD patients from Asia including Japan [9, 10], but no manuscript specific for the elderly. Based on increasing data related to elderly UC patients from Japan, as well as other countries, in the present study, we reviewed the epidemiology, clinical course, differential diagnosis, management of comorbidities, surveillance, medical therapy, and surgery of elderly UC.

Diagnosis and epidemiology in elderly UC patients

Definition of elderly UC patients

The age at which being elderly is defined as is not universally accepted. Elderly people are more likely to have infections, cardiovascular diseases, impaired glucose tolerance, and malignancies compared to young people. The comorbidities and frailties should be considered in defining the age of elderly UC patients, which is often defined as "over 60 years" [7, 8, 11–17] or "over 65 years" [6, 18–22] for convenience, but there is no universal definition currently. Most developed countries have set the chronological age of over 65 years as the definition of an elderly person. Similarly, in Japan, elderly people are often defined as having a chronological age of 65 years or over. However, considering the long life expectancy of the Japanese and its socio-economic influence, some people say that the definition of the elderly should be an individual who is older than 75 years [23]. In this manuscript, we have described the definition of elderly age or older/oldest

²⁰ Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan

²¹ Inflammatory Bowel Disease Center, Toho University Sakura Medical Centre, Sakura, Chiba, Japan

group age, or article type (review, meta-analysis, guideline, and so on) after each reference in the Reference list.

The clinical course in elderly UC patients is reported to be different between elderly patients with late age onset of UC (elderly-onset UC, EOUC) and long-standing elderly UC (LEUC), that is, those who were first diagnosed as having UC at a younger age [22]. Therefore, it is necessary to take the age of onset and the disease duration into account when making decisions regarding the treatment of elderly UC patients.

Epidemiology of elderly-onset UC patients

Shi et al. reported that the number of EOUC patients in Hong Kong increased from 0.1/100,000 in 1991 to 1.3/100,000 in 2010 [17]. In Japan, the number of UC patients has been increasing, with patients more likely to develop the disease between their late 10s and early 30s [9]. Although there are no published statistical data, the age of patients gradually shifts to an elderly population in the aging society and opportunities to encounter elderly UC patients seem to be increasing [9].

The onset of UC is most frequent between 30 and 40 years of age, but previous studies have shown a second peak of incidence in the elderly population [24, 25]. Stowe et al. showed that the incidence in the elderly population (between the ages of 60 and 80 years) was higher than that in the population aged 40–50 years. However, this trend has not been observed in other cohort studies [26, 27]. According to a study by Steven et al., the percentage of newly diagnosed elderly UC patients in the Netherlands was 18.3% in 1991, which increased to 25.9% in 2010 [12].

In a systematic review from an Asian country, Prideaux et al. showed that the age at onset of UC was higher than that of CD, with the average age at onset of UC being 35–44 years [28]. Asakura et al. investigated the number of UC patients in Japan in 5-year age intervals [29] and found that the peak age of incidence was 30–35 years followed by no bimodal peak in the elderly. Takahashi et al. compared the age distribution of UC patients who were diagnosed before 2000 and after 2001. They found that the ratio of EOUC patients increased from 6.3% in those diagnosed before 2000 to 25.9% in those diagnosed after 2001. They also determined that the average age at UC onset was increasing and that a second peak in bimodal distribution of onset shifted to older age [30]. Song et al. reported that the percentage of elderly patients among newly diagnosed patients had increased from 3.9% in 1977–1999 to 9.7% in 2008–2014 [31]. Although the cause the increasing incidence of EOUC in several regions and ethnicities remains unclear, Takahashi et al. reported that past smoking habit is a possible risk factor (OR 2.93) for elderly-onset UC [30]. Araki et al. reported that more than half of the IBD patients

(51.1%) experienced seasonal exacerbation of IBD, and winter was the most common season for disease exacerbation. However, seasonality of disease onset and exacerbation was observed in young-onset patients (≤ 40 years old), but not in elderly-onset patients [32].

Differential diagnosis in elderly patients with UC

As shown in IBD guidelines in Japan [9], it is often necessary to distinguish UC from infectious enterocolitis, especially *Campylobacter*, enteroinvasive *Escherichia coli*, and amoebic dysentery. In addition, immunological dysfunction and lifestyle-related diseases should be taken into consideration to differentiate diagnoses along with the aging. Additionally, since the aging increases the prevalence of lifestyle-related diseases including arteriosclerosis, high blood pressure, diabetes, ischemic heart diseases, and stroke, lifestyle-related diseases and treatment induce colitis necessary to be differentiated from UC (Table 1).

Clostridium difficile (renaming as *Clostridioides difficile* in 2016)-associated diarrhea (CDAD) sometimes occurs in patients using antibiotics or leukopenic patients induced by anti-cancer drugs. The important clinical risk factors for CDAD are advanced age (over 70 years) and long hospital stay (more than 20 days) [33]. Since pseudomembranes, the typical indication of CDAD, are not detected in any of the patients using immunosuppressive agents, bacterial examination is essential when UC becomes exacerbated even in the absence of pseudomembranes [34], in which case ELISA examination of *Clostridium difficile* toxin is one of the useful diagnostic tools. Cytomegalovirus (CMV) colitis often occurs in immunodeficiency patients and in elderly patients [35, 36]. Radiation colitis shows UC-like endoscopic appearances in the cancer patients treated with radiation therapy. Colonic mucosa is a radiation-sensitive organ and radiation-induced injuries often occur in the rectum [37]. Recently, cancer patients have been prescribed immune checkpoint inhibitors, with 1 of the complications being UC-like colitis [38, 39]. The increasing chronic usage of non-steroidal anti-inflammatory drugs (NSAIDs) for orthopedic diseases and proton pump inhibitors (PPIs) for the treatment of gastroesophageal reflux and the prevention of gastrointestinal bleeding due to anti-coagulative drugs sometimes trigger NSAID-induced enteropathy and microscopic colitis, respectively [40, 41]. Patients with microscopic colitis present with chronic diarrhea accompanied by redness, longitudinal ulcers, and scars in the colon. Ischemic colitis often occurs in the elderly patients because of the arteriosclerosis [42]. Idiopathic colitis in the left side colonic diverticulosis is called “segmental colitis associated with diverticulosis, SCAD” [43, 44]. SCAD often occurs in elderly patients and is difficult to differentiate it from UC owing to the similarities

Table 1 Differential diagnosis for ulcerative colitis in the elderly patients**Infection-related diseases***Clostridium difficile* (*Clostridioides difficile*)-associated diarrhea (CDAD)

Intestinal tuberculosis

Cytomegalovirus colitis

Cancer-related diseases

Radiation colitis

UC-like colitis induced by immune checkpoint inhibitors

Lifestyle-related diseases

NSAID-induced intestinal disorder

Microscopic colitis

Ischemic colitis

Segmental colitis associated with diverticulosis (SCAD)

Solitary rectal ulcer syndrome (SRUS)

including endoscopic findings, histology, and good response to mesalazine [45]. Solitary rectal ulcer syndrome (SRUS) is considered to be induced by the mucosal prolapse of the anterior wall by straining during defecation [46]. SRUS results in ulcers and elevated lesions in the rectum, and its pathological features show fibromuscular obliteration. Some cases of SRUS complicated by UC have also been reported [47].

Natural history, disease course, and disease type in elderly UC patients

Symptoms, severity, disease type/extent of elderly UC patients

Major clinical symptoms of UC include hematochezia, diarrhea, abdominal pain, weight loss, and fever and the incidence and severity of these symptoms in EOUC and non-elderly-onset UC (NEOUC) are different according to several reports. In Japan, severity was significantly higher in EOUC patients than in NEOUC patients [6]. However, the disease activity was higher in NEOUC patients than in EOUC patients in France, and Turkey [14, 15]. Meanwhile, there was no difference in disease severity between EOUC and NEOUC in Hong Kong [17]. Taken together, there are no remarkable changes in symptomatic severities between EOUC and NEOUC [7].

In terms of disease distribution, there is a significantly, but only a slightly, wider distribution in Japan of EOUC (EOUC; proctitis:left-sided colitis:pancolitis = 19.5%:34.2%:46.3%, NEOUC; proctitis:left-sided colitis:pancolitis = 23.9%:31.7%:44.5%) [6]. Meta-analysis showed a higher rate of left-sided colitis in EOUC but the rates of disease distributions were almost the same in proctitis and pancolitis between EOUC and NEOUC [8].

In summary, no significant difference was observed in disease severity and distribution between EOUC and NEOUC according to several reports from different countries.

Differences between long-standing elderly UC and elderly-onset UC

Distinguishing between LEUC patients with a longer disease duration and EOUC patients with a shorter disease duration is important as those who have been affected for longer have a lesser frequency of surgery and admission.

The surgical rate in UC patients is higher during the first 2 years after disease onset, which decreases gradually thereafter [48]. Therefore, if we compare the surgical rate and hospital admission rate of elderly EOUC and LEUC patients of the same age, it would be higher in EOUC patients because disease duration is shorter in EOUC than in LEUC. In a study by Matsumoto et al., the rate of steroid use was recorded in 58% of EOUC patients, but 0% of the LEUC patients during disease exacerbations. Resistance to or dependence on prednisolone was observed in 17% of EOUC patients. The rate of hospital admission due to exacerbation of UC was 25% and the rate of emergency surgery was 17% in EOUC patients. On the other hand, none of the LEUC patients were admitted to the hospital or underwent surgery during the study period [22].

It is well known that LEUC patients are at an increased risk for colorectal cancer because of the long duration of the disease [49, 50]. However, whether the risk for colorectal cancer increases more in older patients compared with younger patients with the same disease duration has not been examined in detail [51, 52]. On the other hand, surveillance for the development of colorectal cancer in patients with elderly-onset IBD is recommended based on the evidence that elderly-onset IBD is associated with an increased risk for colorectal cancer. Furthermore, the time

to the development of colorectal cancer decreases by 0.154 point per 1 year increment of age [53]. The following statement was made by the European Crohn's and Colitis Organization (ECCO) in 2017: "The screening program in the elderly should be balanced with disease severity, comorbidities, and life expectancy" [7].

Hospitalization and surgery in elderly UC patients

Previously, studies have reported that the surgery rate of elderly UC patients is similar to that of non-elderly patients [12, 13, 18] with other studies reporting the converse, that the surgery rate of elderly patients is lower than that of non-elderly patients [14, 48]. The topical review of ECCO also says that the surgery rate of elderly UC patients does not differ from that of non-elderly patients. [7]. On the contrary, a recent meta-analysis targeting only EOUC reported a 1.36-fold higher surgical rate [8]. One of the possible reasons for the controversial results was that previous studies did not consider the onset of the disease or disease duration, which includes not only EOUC but LEUC, which is generally considered to be a less severe course of the disease [15]. Recently, similar results were reported from Asian countries [22, 54]. It has been reported that the surgery rate was significantly higher in EOUC patients than in NEOUC patients in a large-scale cohort study in Japan. One of the reasons why EOUC has a higher surgery rate is that EOUC patients have less chances of receiving strong immunosuppressive therapies owing to comorbidities and adverse events, such as infections [19, 55]. In addition, some reports showed that the peri-operative mortality rate rises in emergency surgeries [16, 20], and life prognosis will be improved by early operations in elderly UC patients [56].

There are many reports that the hospitalization rate of elderly UC patients is significantly higher than that of non-elderly UC patients [7, 12, 17, 21, 22]. Moreover, it has been reported that the hospitalization rate is significantly higher in EOUC in a large-scale cohort study in Japan [6], probably due to more severe disease at onset, more comorbidities, and a higher risk for infectious events due to immunosuppressive therapies in elderly patients.

Management for complications and comorbidities in elderly UC patients

The significance of vaccination in elderly UC patients

In general, elderly people have an increased risk for infection based on a weakened immune system compared with non-elderly people [9]. Furthermore, UC patients

treated with immunosuppressive agents such as corticosteroids, immunomodulators, or molecular-targeted agents are at an increased risk for infectious diseases [7, 57, 58], especially in UC patients treated with corticosteroids or multi-immunosuppressive agents [7, 55].

All UC patients should be tested for hepatitis B virus (HBV) at UC diagnosis to determine HBV status. Furthermore, an HBV vaccination is recommended in all HBV anti-HBc Ab-seronegative UC patients [59]. Many IBD patients were unaware of their past vaccinations or infections with the viruses causing varicella zoster, rubella, measles, or mumps [60], which are live vaccines (the recombinant subunit vaccine for herpes zoster virus (HZV) was approved in Japan at March 2018). Therefore, measuring the current levels of antibodies specific for these viruses is useful before administration of immunomodulators/biologics. Please refer to the previous guides for details about the vaccines mentioned above [59, 61].

Elderly UC patients (especially in Asia) treated with tofacitinib are at increased risk for herpes zoster [62]. The recombinant subunit vaccine for HZV (HZ/su, Shingrix[®]) [63], which is not a live vaccine and reduces the risk for herpes zoster among adults 70 years or older, was approved in Japan in March 2018. The effectiveness of the vaccine remains to be clarified in elderly UC patients. The pneumococcal vaccine and influenza vaccine, both inactivated vaccines, are often administered in elderly UC patients. The appropriate timing of pneumococcal vaccination should be considered when needed clinically except the regularly offered vaccination. On the other hand, annual influenza vaccinations are recommended in elderly UC patients [55, 61]. The inactivated vaccination can be administered even to UC patients who are treated with immunosuppressive agents such as anti-TNF; however, there is a possibility to reduce the immune response for influenza vaccinations in the elderly. [64]. The twice booster influenza vaccination is not effective with regard to increasing the immune response in adult IBD patients, unlike pediatric IBD patients [65].

Influence of comorbidities

The proportion of IBD patients older than 65 years who have 3 or more comorbidities is 9.6%, which is higher than that of patients younger than 65 years (2.6%) [21]. In elderly IBD patients, the most common complications are diabetes (16.8%), heart diseases (such as myocardial infarction and congestive heart failure) (3.4%), chronic lung disease (21.4%), and cerebrovascular disease (3.1%). The risk for nephrotoxicity, particularly in elderly patients with IBD, which is complicated by heart failure or renal dysfunction, increases due to delayed excretion of 5-aminosalicylic acid (5-ASA). Therefore, it is

unsustainable to administer a sufficient dose of 5-ASA and that could possibly lead to a deteriorated clinical course of IBD [11]. In addition, the risk for malignant tumors unrelated to IBD is higher in elderly IBD patients [21]. It has been reported that the proportion of cholangiocarcinoma is higher in solid cancers arising outside the gastrointestinal tract, and its risk increases with advancing age [66].

It is reported that the in-hospital mortality rate of elderly IBD patients (aged 65 and older) is higher than that of young IBD patients (19–64 years old), and the adjustment odds ratio of death rate also increases with the Charlson Comorbidity Index [21]. In addition, the presence of complications has a significant influence on the postoperative outcome in elderly IBD patients. Kaplan et al. [67] reported that among older surgical patients who underwent IBD-related surgery, the postoperative mortality rate increased as the number of complications increased. Complications of congestive heart failure, liver disease, thromboembolism, and renal disease are associated with a significant increase in mortality. Upon emergency surgery, the postoperative mortality rate of elderly people (65–80 years old) with 2 or more complications was the highest (20.6%). On the other hand, the mortality rate of patients with 2 comorbidities or fewer was 11.0%. In elective IBD surgery, the mortality rates of elderly patients with 2 or more comorbidities and less than 2 comorbidities were low, at 7.7% and 2.8%, respectively.

Infectious diseases

Ananthkrishnan et al. analyzed an inpatient database in the US and presented that age was identified as an independent risk factor for hospitalization due to infectious complications such as pneumonia, sepsis, urinary tract infection, and *C. difficile* infection in IBD patients [68]. Toruner et al. later reported that increased age and immunosuppressive medications such as corticosteroids, especially when used in combination, were associated with an increased risk for opportunistic infections among IBD patients, and that those first evaluated older than the age of 50 years had significantly greater odds to have been diagnosed with an opportunistic infection (odds ratio 3.0; 95% CI 1.2–7.2) [55]. Furthermore, Naganuma et al. investigated risk factors of opportunistic infections in a 1-year cohort study and reported that an age of 50 years and older as well as use of immunomodulators were identified as independent risk factors of having opportunistic infections [57]. Furthermore, age was found to be independently associated with increased mortality. Cottone et al. reported that IBD patients older than 65 years treated with infliximab or adalimumab have a high rate of severe infections and mortality compared with younger patients or patients of the same age that did not receive these therapeutics [19].

Brassard et al. identified and investigated more than 3500 IBD patients who had developed IBD at age 66 and older from the Quebec healthcare database and reported that corticosteroid use was associated with serious infections [69].

Regarding the risk for *C. difficile* infection, Das et al. investigated if corticosteroids increased the mortality in patients with CDAD, including IBD patients, and concluded that the mortality of patients with CDAD on corticosteroids was significantly higher than the mortality of patients with CDAD not on corticosteroids, where both in corticosteroid users and non-users, patient age was an independent risk factor for mortality in the multivariate analysis [70]. Nguyen et al. investigated the discharge summaries of IBD patients in US National Inpatient Sample and reported that UC patients had higher prevalence and mortality of *C. difficile* infection than those with CD, non-IBD gastroenterology or general medical patients [71].

Gupta et al. reported that in their retrospective analysis of herpes zoster infections among IBD patients in the UK General Practice Research Database, both UC and CD patients had higher incidences than in the general population. In a nested case–control study including 451 IBD patients and 1787 controls [72], use of corticosteroids and immunosuppressive medications was presented to be associated with zoster which also showed, compared with people aged 5–44, a roughly two- to threefold increased risk among patients aged 45–64, and a fourfold increased risk among patients aged 65 and older. Furthermore, in Asia, Tsai et al. investigated the Research Database of Taiwan National Health Insurance and reported that male IBD patients had a higher risk for herpes zoster in age groups of 35–44 and 65 and more [73]. In a retrospective analysis of zoster among UC patients who had participated in the tofacitinib development programs, age over 65 years and refractoriness to anti-TNF α treatment were both reported to be independent risk factors [62].

On the other hand, the safety and efficacy of vedolizumab, anti- $\alpha_4\beta_7$ integrin, in UC patients were similar for all age groups in a subgroup analysis of GEMINI-1, phase III trials [74].

Surveillance in elderly UC patients

The risk for colorectal cancer is elevated in UC patients with long-term disease duration, but it is not clear whether the risk for colorectal cancer will increase in the elderly UC itself [49, 75]. There is no evidence that the risk for colorectal cancer is different between elderly and non-elderly UC patients [51]. Thus, there is no reason to change the surveillance method by age of disease onset.

However, in elderly UC, there are many cases whose onset time is unclear because of vague clinical symptoms [76], and it is possible that a long period of time has passed since disease onset at the time of diagnosis. Thus, it is necessary to start the surveillance program earlier in the patients whose onset time is unclear.

Colorectal cancer surveillance should be carried out in consideration of the balance between benefit and risk such as age, life prognosis, complication of other diseases including malignant tumors other than colorectal cancer, and risk for endoscopy [77].

General attention of medical therapy for elderly UC patients

Efficacy of medical therapy for elderly UC patients

Despite a few reports comparing the efficacy of individual medical treatments in non-elderly UC patients to that in elderly UC patients, there is no clear evidence that the efficacy obtained in non-elderly UC patients cannot be expected in elderly UC patients [7]. Therefore, all medical treatments are thought to be potential treatment options in elderly UC patients as well. In fact, medical treatments used in non-elderly UC patients are also selected for elderly UC patients in Japan [6, 22].

However, when considering medical treatments in elderly UC patients, one should pay attention to the interaction between comorbid diseases and their treatments; furthermore, a treatment needs to be decided whilst considering the characteristics of each patient, including susceptibility to infection and cancer risk. In fact, the frequency of adverse events such as infection and tumorigenesis is high in elderly UC patients who are treated with corticosteroids, thiopurine agents, or biological agents, and careful attention should be paid when administering these drugs [7, 76, 78]. Therefore, when selecting a medical treatment for elderly UC patients, risks associated with treatment should be considered on a case-by-case basis, especially as many new treatment options for IBD become available in the future [79]; dosages may have to be kept low in elderly UC patients and one should note that the efficacy may consequently decrease.

Moreover, in elderly patients with severe or intractable UC, one should perform medical treatments carefully considering various comorbidities and reduced physiological reserves, and always keep in mind not to miss an opportunity to refer for surgery in a proper timing.

The standard therapy for UC, 5-ASA agents, can be safely used in elderly UC patients; the efficacy in elderly patients was reported to be similar to that of non-elderly patients in most studies [78]. In studies of both elderly UC

patients and elderly individuals without UC, the tolerance to topical formulations in enemas may decrease due to the decreased function of the anal sphincter [76].

Although there has not been a detailed study to examine the efficacy of corticosteroids in elderly UC patients, the efficacy is thought to be similar to that in non-elderly UC patients [80]. The rate of corticosteroid administration in elderly UC patients varies depending on studies [13, 18]. A nationwide survey in Japan reported a high rate of corticosteroid use in elderly UC patients [6].

The rate of thiopurine use in elderly UC patients is not high worldwide [18], including in Japan [22]. There have been no reports comparing the efficacy of thiopurine agents in elderly UC patients to that in non-elderly UC patients; however, the efficacy is thought to be similar [80]. Conversely, the risks of infection and malignant disease such as lymphoma have been observed to increase in elderly UC patients [81].

With respect to anti-TNF- α antibody agents, a study reported that in elderly UC patients treated with anti-TNF- α antibody agents, the rate of clinical improvement was lower than that in non-elderly UC patients during a short period (week 10 of administration); however, it was equal over a long period (over 6 months), suggesting that a certain period of time may be required until a curative effect is evident in elderly UC patients [82]. In contrast, it was reported that the therapeutic effect was low at 6 months after the initiation of administration and the rate of discontinuation was reported to be high in elderly UC patients [83], which may be particularly due to vulnerability to infectious complications requiring hospitalization.

The effect of therapeutic cytopheresis (CAP) in elderly UC patients is reported to be similar to that in non-elderly UC patients [84], whereas there is a contradictory report showing attenuation in its effect in elderly UC patients [85]. Thus, the efficacy of CAP in elderly UC is not consistent.

The efficacy of tacrolimus in elderly UC patients was only shown in a number of case reports and it has not been fully examined [86, 87]. Therefore, the difference in its efficacy between elderly and non-elderly patients remains unclear.

The efficacy of vedolizumab, an anti- $\alpha_4\beta_7$ integrin antibody agent, in elderly UC patients was reported to be similar to that in other age groups in the sub-analysis, grouped by age (< 35 years, 35–54 years, and \geq 55 years), of a phase III trial (GEMINI-1) [74].

There have been no reports on the efficacy of tofacitinib, a JAK inhibitor, in elderly UC patients. However, the sub-analysis of interview forms for pharmaceutical approval in the phase III trial of remission induction/maintenance therapies conducted in Japan and elsewhere has shown

similar efficacy in elderly and non-elderly UC patients [88].

Polypharmacy and drug interactions among elderly UC patients

Basically, there are no drugs that cannot be used for treatment of elderly UC [11, 89]. However, use of multiple drugs due to many concomitant diseases in addition to low organ reserve capacity will increase the risk for adverse drug reactions [11].

On the other hand, “polypharmacy” is of particular concern in the elderly due to the high possibility of difficulty in self-manage medication, leading to decreased adherence rates. Elderly patients with several comorbidities take multiple drugs (more than 5 drugs on average). Reportedly, 25% of the patients consume more than 6 types of drug [89]. Therefore, in elderly IBD patients with comorbidities, it is necessary to pay attention to the lower compliance rate and drug interaction caused by multiple drug therapy [89]. It has been shown that the clinical activity of IBD significantly increased in elderly depressive IBD patients through reduced medication adherence [90].

The risk for drug interaction rises according to the number of medicines prescribed: 13% for 2 or more kinds, 38% for 4 kinds, and 82% for 7 kinds [89]. Among them, the anticoagulant effect of warfarin potassium needs special attention. The mesalazine formulation enhances the anticoagulant effect because it inhibits the metabolism of warfarin potassium [91]. Corticosteroids attenuate the anticoagulant action of warfarin potassium by its coagulation accelerating action. Thiopurine formulation may also reduce the anticoagulant action of warfarin potassium [92]. In addition, allopurinol enhances thiopurine efficacy [93]. The mesalazine formulation also may enhance thiopurine efficacy by inhibiting thiopurine methyl transferase activity [94]. There is a possibility that the risk for bone marrow suppression and infectious diseases may be further enhanced especially in elderly UC patients.

Corticosteroid-treated elderly IBD patients have been reported to have a significantly increased risk for developing osteoporosis-related bone fractures, changes in mental state such as depression, deterioration of diabetes, hypertension, and glaucoma [95]. As the clinical course of IBD in these patients may be adversely affected, it is of utmost importance to limit the dose of corticosteroids in elderly IBD patients with the comorbidities.

In elderly individuals, although the rate of consuming anticoagulants and antiplatelet drugs for coronary artery disease, heart disease, and cerebrovascular disease is high, there is no evidence that antiplatelet therapy increases the frequency of IBD relapses. In a survey of 41 IBD patients who consumed aspirin and clopidogrel for coronary artery

disease, there was no difference in the frequency of IBD relapses as compared with that of the control group. Indeed, patients treated with antiplatelet therapy showed an 11% reduction in IBD relapse [96]. Therefore, there is no reason to support the discontinuation of aspirin medication in IBD patients with cardiovascular complications [97, 98].

Medical therapy for elder UC patients

Steroids

Administration of adrenocorticosteroids (steroids) is recommended for the treatment of moderate-to-severe UC patients [9]. However, in using steroids for elderly UC patients, it is of particular importance to pay attention to infectious diseases in addition to side effects such as osteoporosis, osteonecrosis, edema, and cataracts. Generally, elderly people have a higher risk for infectious diseases due to an age-related decline in immune cell function and physical performance. Toruner et al. [55] reported that the use of corticosteroids is an independent risk factor for opportunistic infections in elderly IBD patients. Brassard et al. [69] reported that there was a correlation between the use of steroids and the development of a severe infectious disease in elderly-onset IBD patients. Komoto et al. reported that the proportion of patients using corticosteroids was significantly higher in EOUC patients than in NEOUC patients [6]. With regard to infectious diseases, Gupta et al. reported that the incidence rate of herpes zoster was higher among elderly IBD patients compared to healthy individuals. Furthermore, the risk was high among patients who used corticosteroids or immunomodulators [72]. From the cohort study conducted in France including 472 EOUC patients [15], risk factors for a colectomy in EOUC patients were investigated, which showed that the extent of disease distribution and the history of corticosteroid use were significant risk factors. However, by multivariate analysis, only the history of steroid use was found to be a significant risk factor. From these reports, we should pay attention not to administer corticosteroids to elderly UC patients for a prolonged period.

Thiopurine

Thiopurine (azathioprine, 6-mercaptopurine) is effective and safe for maintaining remission of UC, and its effectiveness has been reported in Japan [99, 100]. Sustained thiopurine use of more than 1 year in EOUC patients was associated with a 70% reduction in risk for colectomy [hazard ratio (HR) 0.30; 95% CI 0.15–0.58] [101]. A

combination of thiopurine and infliximab showed a twofold greater effect for steroid-free remission than thiopurine monotherapy in the UC SUCCESS trial (39.7% vs. 22.1%, $p = 0.017$) [102]. However, the benefit of combination therapy for the elderly has not been confirmed as elderly patients were not included in this trial. Combination immunosuppression therapy was a significant predictor of anti-TNF cessation with a 2.2-fold increase in the likelihood in elderly anti-TNF users [83]. Thus, it is necessary to remain cautious about the use of combination therapy in the elderly.

Regarding adverse effects related to thiopurine, there was higher incidence of hepatotoxicity and a lower incidence of acute pancreatitis in the elderly-onset IBD patients [103]. In addition, older age alone is considered as a risk for opportunistic infection [55]. Furthermore, patients receiving thiopurine also have a greater risk for opportunistic infections (i.e., herpes simplex virus, HZV, CMV, and Epstein–Barr virus) and tuberculosis (TB) [57, 104].

The use of thiopurines has been shown to be associated with an increased risk for lymphoproliferative disorder in several studies [9, 10, 105–107]. The CESAME study, a multicenter prospective cohort study from France, showed that continuing thiopurine therapy, older age, and a longer duration of IBD were the main risk factors for lymphoproliferative disorder [9, 10, 106]. Meta-analysis showed that the risk for lymphoma rises approximately 4–5 times in IBD patients treated with thiopurines [10, 105, 107]. The risk for lymphoma increased especially in IBD patients older than 50 years [108]. The use of anti-TNF monotherapy (HR 2.60; 95% CI 1.96–3.44) and thiopurine monotherapy (HR 2.41; 95% CI 1.60–3.64) has a significantly increased risk for lymphoma, respectively, and this risk becomes approximately 2 times higher with combination therapy than each of these treatments used alone according to the French National Health Insurance claim database [109]. However, a multicenter retrospective study in Japanese patients with IBD suggested that thiopurine may not be a risk factor of hematologic malignancies; therefore, further examination is necessary for Japanese IBD patients [110].

An increased risk for non-melanoma skin cancer associated with thiopurine use has been found in the American database (the LifeLink Health Plan Claims Database) with approximately 110,000 IBD patients from 1997 to 2009 [111]. In addition, present thiopurine exposure increases the risk for non-melanoma skin cancer, particularly in the elderly Caucasian population [112]. However, there is a lack of data in the Japanese IBD patients regarding association between thiopurine use and non-melanoma skin cancer.

Tacrolimus

Tacrolimus is an immunosuppressant known to inhibit the production of cytokines including IL-2 [113] used for solid organ transplantation [114], rheumatoid arthritis [115], and refractory UC [116].

While the effectiveness of tacrolimus in the induction of remission of UC has been demonstrated [117, 118], side effects, such as nephrotoxicity, neurotoxicity, hypertension, and secondary infections, are known to develop depending on trough concentration. [118]. The effectiveness and safety of tacrolimus in elderly UC patients has only been detailed in case reports [86, 87, 119].

Elderly UC patients are susceptible to various complications, such as renal insufficiency and hypertension, and are also prone to infections [7, 11, 59]. Furthermore, infection is a risk factor of hospitalization [68]. In this regard, the rate of opportunistic infections increases in patients with IBD after the age of 50 [55, 57], which is considered a critical factor leading to death [11]. Cyclosporin, another calcineurin inhibitor, is not recommended for elderly UC patients older than 60 years as it may aggravate complications [120, 121]. The rate of cyclosporine and tacrolimus use in European patients ≥ 65 years of age is only $< 0.5\%$ (2004–2009) [122]. When using calcineurin inhibitors in elderly UC patients, it is necessary to accurately evaluate renal and other organ functions [86, 123]. In addition, in patients treated with several immunotherapeutic agents, including tacrolimus, administration of prophylactic agents against opportunistic infections is highly recommended [59, 119]. Tacrolimus is metabolized by cytochrome P450 3A enzymes. Older patients often use several drugs for various complications, and it is important to check for potential interactions with agents that have the same metabolic pathway, such as nifedipine (Ca antagonist) and lansoprazole (PPI).

There is a paucity of information on optimal tacrolimus dosage and target trough concentration in the elderly, even in diseases out with UC. Furthermore, the initial dosage of tacrolimus has not yet been set for elderly kidney transplant recipients relative to their younger counterparts [124]. Thus, it is important to monitor tacrolimus blood trough concentrations in the elderly during the maintenance phase of treatment [124]. It has been reported that the infection rate was within an acceptable range in patients, with an average age of 61 years ranging from 50 to 77 years old, who were treated by tacrolimus for renal transplantation [125]. In patients with rheumatoid arthritis, the routinely used dose of tacrolimus is 3 mg/day, whereas the recommended starting dose for those aged more than 65 years is 1.5 mg/day [115]. Aging beyond 65 is associated with increased risk for renal dysfunction, thus treating elderly

patients with tacrolimus is a risk factor of nephropathy [126].

Anti-TNF α agents

Currently, 3 types of anti-TNF agents (i.e., infliximab, adalimumab, and golimumab) can be used to treat patients with moderate-to-severe UC in whom existing drug therapy has been ineffective.

In a multicenter, prospective study conducted in Italy for 10 years, the anti-TNF agents infliximab and adalimumab were administered to 2,475 and 604 IBD patients, respectively, to compare the occurrence of infections, malignant neoplasms, and death. The comparison of elderly and non-elderly findings revealed the rates of infection (13% vs. 2.6%), malignant neoplasms (3% vs. 0%), and death (10% vs. 1%), suggesting that occurrence rates were elevated in elderly patients [19]. In addition, a study reported that the risk for malignant neoplasms and infections among patients aged > 65 years who received anti-TNF agents was 4.7 times higher than those among non-elderly patients [82]. Hence, anti-TNF agents should be administered to elderly patients with caution.

The risk for TB increases with age and anti-TNF administration. Therefore, TB should be screened for before treating with immunomodulators or biologics [127]. Furthermore, treating adult patients with CD with anti-TNF agents alone or combined with immunomodulators increases the risk for developing non-Hodgkin's lymphoma [109]. Moreover, the risk elevation tends to occur more often among male and elderly patients [128, 129].

Concerning the incidence of death related to anti-TNF agents, a study comparing 734 anti-TNF-treated and 666 anti-TNF-untreated patients reported that the age at anti-TNF induction was the single independent factor causing death [130]. Furthermore, 75% of infliximab-related deaths occurred among patients aged > 65 years. It is reported for Crohn's disease that patients who died had the disease for a long period of time (15–26 years), had severe disease activity and complications, and used immunomodulators in combination [131]. On the other hand, the risk for severe infection does not change between treatment with anti-TNF agents alone and with a combination of anti-TNF agents and immunomodulators [19].

Deaths due to cardiovascular events that developed after the anti-TNF administration have been reported [82]. Therefore, the cardiac functions should be screened before administering anti-TNF agents. Anti-TNF could be used for patients with an ejection fraction > 50% and well-compensated heart failure (NYHA class I–II). The use of anti-TNF drugs for patients having severe heart failure (NYHA class III–IV) elevates mortality rate, rendering their use unsuitable [132]. Anti-TNF agents have been

shown to increase death related to heart failure among patients with rheumatoid arthritis [132]. Hence, cardiac function should be monitored in patients with heart failure.

Cytapheresis

There are a few reports on the efficacy and safety of CAP in elderly UC patients [84, 85, 133]. These reports highlighted the safety of CAP in elderly patients because the incidence of adverse events (AEs) for CAP is not different between elderly patients and the non-elderly patients with UC. Komoto et al. determined in their retrospective multicenter cohort study ($n = 847$) that the incidence of AEs was 8.0% in the elderly UC patients and 10.5% in non-elderly patients [133]. They also reported that most AEs were mild events such as nausea or a mild decrease in platelet counts; severe AEs such as severe infection or thrombosis were not observed. Moreover, Ito et al. reported that CAP is a safe therapy for elderly UC patients as there were only mild AEs such as headache or allergic reaction to anticoagulants [84].

Surgical treatment in elderly UC patients

Indication of surgical treatment

In general, the absolute indications for surgery in patients with UC include bowel perforation, uncontrollable bleeding, toxic megacolon and colitis-associated colorectal cancer. The relative indications for surgery include refractory disease with failure of medical management.

Elderly UC patients are more frequently operated on due to severe or fulminant disease compared to non-elderly patients [134, 135]. Because elderly UC patients have few subjective symptoms even in severe or fulminant disease, it is difficult to judge the indication of surgery in elderly patients. Therefore, the disease activity and patient condition should be more carefully evaluated in elderly UC patients.

In elderly patients, surgery with the permanent colostomy is more often selected, because the sphincter-preserving procedure cannot be performed due to deterioration of anal sphincter function [134, 135].

Timing of surgical treatment

Elderly people often have concomitant complications, such as cardiovascular disease and diabetes, which could affect surgical prognosis [134]. Therefore, surgery should be performed before the general status gets worse [136].

Elderly UC patients with pneumonia and thrombosis during hospitalization increases postoperative mortality, especially in the case of emergent surgery [134].

The timing of elective surgery does not have to be changed between non-elderly and elderly UC patients with relatively good general condition in the case of the patients with early colitis-associated colorectal cancer.

On the other hand, early determinations for surgery should be considered in patients with severe complications, with severe or fulminant disease activity, or refractory to medical treatments, because their postoperative course was worse compared to non-elderly patients if the timing of surgery is the same [7, 136]. In elderly patients, the ratio of patients whose ADL has weakened after the surgical procedure was high, leading to development of pneumonia, difficulty in ambulation, and the deterioration of swallowing. Thus, elderly patients need to be determined for the early surgical treatment before their ADL get lower.

Selection of surgical procedure

Elderly UC patients tend to decrease general condition, organ function, anal sphincter function, or ADL compared with non-elderly UC patients. Under the consideration of these factors, surgical procedures should be determined to be safe and maintain patients' quality of life [7]. Preoperative sufficient informed consent is also important.

Following 5 surgical procedures are generally selected: (1) ileal pouch anal anastomosis with mucosectomy (hand-sewn IPAA), (2) stapled ileal pouch anal anastomosis (stapled IPAA), (3) ileorectal anastomosis (IRA), (4) total proctocolectomy with end ileostomy (TPC), and (5) subtotal colectomy with end ileostomy, mucous fistula of the sigmoid colon, or Hartmann's operation.

Some papers reported that sphincter-preserving surgery (hand-sewn or stapled IPAA) resulted in good functional outcome in elderly UC patients, if the patients had a good anal sphincter function and good ADL preoperatively [134, 137–140]. On the other hand, it is also reported that sphincter-preserving surgery for elderly UC patients tended to increase long-term postoperative complications [139] and decrease bowel function [137, 140, 141]. Functional outcome after stapled IPAA is reported to be better compared with that after hand-sewn IPAA because anal canal tissue is preserved in stapled IPAA [137, 142].

In elderly UC patients with impaired sphincter function or lower ADL, total colectomy + IRA or TPC is usually selected in consideration of postoperative functional outcomes. Stapled IPAA and IRA preserve the diseased mucosa; therefore, it is important to pay attention to the risk for relapse or cancer [9]. In the case of emergent surgery with poor general conditions, less invasive surgical procedures such as subtotal colectomy with end ileostomy,

mucous fistula of the sigmoid colon, or Hartmann's operation should be selected first [16]. Surgical procedures accompanied with stoma construction are more often selected in elderly UC patients compared with non-elderly UC patients [16, 143].

In cancer cases, surgical procedures for elderly UC patients should be carefully determined in consideration of performance status, extension of colitis, organ function, ADL, advance of cancer, and colitis-associated cancer or sporadic cancer. In the case of colitis-associated cancer, total proctocolectomy is usually selected in consideration of the risk for cancer at the other colorectal site. If the patients had a good anal sphincter function and good ADL, hand-sewn IPAA can be offered. On the other hand, TPC with permanent end ileostomy is usually selected if the patients impaired sphincter function, lower ADL, or advanced cancer located in lower rectum or anal canal. Stapled IPAA is not usually selected in consideration of the risk for cancer at the remnant anal canal; however, it is sometimes selected in comprehensive consideration of patients' condition. When stapled IPAA is performed, close follow-up for the remnant anal canal is required [141]. If the general condition is too poor to undergo total colectomy, ordinary segmental colectomy is performed in consideration of safety and postoperative QOL. In the case of sporadic cancer, ordinary segmental colectomy can be also selected. In these cases, postoperative follow-up for the remnant colorectal tissue is required.

Postoperative complications and prognosis after surgical treatment

It is generally recognized that older age regardless of disease is an independent risk factor for surgical mortality and morbidity [144]. However, some cohort studies of patients with UC have suggested that those were similar among several age groups [143]. Nevertheless, it is commonly agreed that infectious complications and venous thrombosis, known to be increasing in older patients regardless of surgical treatments, must be considered during treatment for UC [19, 83, 130]. Although pouch surgery for UC has been shown to be safe, and surgical morbidity and mortality are similar regardless of age, emergent surgery and concomitant complications with other systematic diseases, such as heart disease or pulmonary disease, are shown to be prognostic factors in the surgical treatments for older patients [20, 137, 138, 145, 146]. In a study conducted in Japan, surgical mortality in the older group who received an emergency procedure was at a rate of 26.7% within 30 postoperative days [16], though surgical morbidity and mortality were similar between patients of older age and younger age.

In conclusion, the rates of surgical morbidity and mortality may be increasing in older patients with UC in

association with the method of surgical procedure, or concomitant complications with other systematic diseases. Notably, it is important to highlight that emergency surgery for older patients elevates the risk for surgical morbidity and mortality.

Influence of surgical treatment on anal function and daily life

Generally, anal function deteriorates with aging, while it has also been reported that it can progressively worsen and fecal incontinence increases after ileal pouch anal anastomosis for UC in older patients [147]. Another study noted that the incidence of night time fecal incontinence may be higher in patients older than 65 years as compared to younger patients, though stool frequency was not found to change with aging [138]. On the other hand, no relationship between aging and fecal incontinence after pouch surgery was seen in several other reports [139, 148, 149]. Although opinions vary, an interesting study recommended a stapled, not hand-sewn, anal anastomosis to maintain anal function in older patients [89].

In a study conducted in Japan, the prevalence of stapled anal anastomosis was higher in patients older than 60 years as compared to the younger group [16]. They noted that a stapled anal anastomosis or permanent ileostomy had tendencies to be used as a standard surgical procedure for elderly patients. As for anal anastomosis, another report noted that anal function after a stapled anastomosis was similar between non-elderly and elderly patients [134]. However, it is important to consider operative method of anastomosis for older patients, because anal function deteriorates following a hand-sewn procedure in association with aging, even though good QOL can be maintained in most cases [140].

A permanent ileostomy can contribute to maintain the good QOL, such as with a restorative proctocolectomy. In some older patients, there are no restrictions or issues with defecation following a permanent ileostomy, with improved QOL similar to that seen in younger patients or after a restorative proctocolectomy [150]. In cases with mild inflammation or with low risk for developing colitis-associated cancer, an IRA is occasionally recommended for older patients to preserve anal function [89].

In conclusion, even though pouch function may become worse in older patients with UC, QOL can be maintained at the same level as prior to surgery with a proper surgical procedure.

Acknowledgements This research was supported by Research on Intractable Disease, Health and Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare, Japan.

Compliance with ethical standards

Conflict of interest Any financial relationship with enterprises, businesses, or academic institutions in the subject matter or materials discussed in the manuscript are listed as follows: (1) those from which the authors have received individually any income, honoraria or any other types of remuneration: Abbvie Inc., EA Pharma Co., Ltd., Janssen Pharmaceutical K.K., JIMRO Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd, Yakult Honsha Co., Ltd, Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Ltd., Pfizer Inc., Takeda Pharmaceutical Company Limited, and Zeria Pharmaceutical Co., Ltd.; and (2) those from which the academic institutions of the authors received support (commercial/academic cooperation): Abbvie Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., EA Pharma Co., Ltd., JIMRO Co., Ltd., Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd. Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Ltd., MSD K.K., Nippon Kayaku Co., Ltd., and Takeda Pharmaceutical Company Limited.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

References

1. Director-general for statistics and information policy. Abridged life tables for Japan 2017: Ministry of Health, Labour and Welfare. 2018. <https://www.mhlw.go.jp/english/database/db-hw/lifetb17/dl/lifetb17-01.pdf>. Accessed 26 Mar 2019.
2. Current population estimates as of October 1, 2017: statistics bureau and the director-general for policy planning of Japan 2018. <https://www.stat.go.jp/english/data/jinsui/2.html>. Accessed 26 Mar 2019.
3. Ananthakrishnan AN. Epidemiology and risk factors for IBD. *Nat Rev Gastroenterol Hepatol*. 2015;12:205–17 (**no definition of elderly**).
4. Ananthakrishnan AN, Bernstein CN, Iliopoulos D, et al. Environmental triggers in IBD: a review of progress and evidence. *Nat Rev Gastroenterol Hepatol*. 2018;15:39–49 (**no definition of elderly**).
5. Japan Intractable Diseases Information Center. <http://www.nanbyou.or.jp/entry/62>. Accessed 26 Mar 2019.
6. Komoto S, Higashiyama M, Watanabe C, et al. Clinical differences between elderly-onset ulcerative colitis and non-elderly-onset ulcerative colitis: a nationwide survey data in Japan. *J Gastroenterol Hepatol*. 2018;33:1839–43 (**elderly \geq 65 y.o.**).
7. Sturm A, Maaser C, Mendall M, et al. European Crohn's and colitis organisation topical review on IBD in the elderly. *J Crohn's Colitis*. 2017;11:263–73 (**review, elderly \geq 60 y.o.**).
8. Ananthakrishnan AN, Shi HY, Tang W, et al. Systematic review and meta-analysis: phenotype and clinical outcomes of older-onset inflammatory bowel disease. *J Crohns Colitis*. 2016;10:1224–36 (**meta-analysis, elderly \geq 50 y.o.**).
9. Matsuoka K, Kobayashi T, Ueno F, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. *J Gastroenterol*. 2018;53:305–53 (**guideline**).
10. Shi HY, Ng SC. The state of the art on treatment of Crohn's disease. *J Gastroenterol*. 2018;53:989–98 (**review**).

11. Gisbert JP, Chaparro M. Systematic review with meta-analysis: inflammatory bowel disease in the elderly. *Aliment Pharmacol Ther.* 2014;39:459–77 (**meta-analysis, elderly \geq 60 y.o.**).
12. Jeuring SF, van den Heuvel TR, Zeegers MP, et al. Epidemiology and long-term outcome of inflammatory bowel disease diagnosed at elderly age—an increasing distinct entity? *Inflamm Bowel Dis.* 2016;22:1425–34 (**elderly \geq 60 y.o.**).
13. Lakatos PL, David G, Pandur T, et al. IBD in the elderly population: results from a population-based study in Western Hungary, 1977–2008. *J Crohns Colitis.* 2011;5:5–13 (**elderly \geq 60 y.o.**).
14. Kalkan IH, Dagli U, Oztas E, et al. Comparison of demographic and clinical characteristics of patients with early vs. adult vs. late onset ulcerative colitis. *Eur J Intern Med.* 2013;24:273–7 (**elderly \geq 60 y.o.**).
15. Charpentier C, Salleron J, Savoye G, et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. *Gut.* 2014;63:423–32 (**elderly \geq 60 y.o.**).
16. Ikeuchi H, Uchino M, Matsuoka H, et al. Prognosis following emergency surgery for ulcerative colitis in elderly patients. *Surg Today.* 2014;44:39–43 (**elderly \geq 60 y.o.**).
17. Shi HY, Chan FK, Leung WK, et al. Natural history of elderly-onset ulcerative colitis: results from a territory-wide inflammatory bowel disease registry. *J Crohns Colitis.* 2016;10:176–85 (**elderly \geq 60 y.o.**).
18. Juneja M, Baidoo L, Schwartz MB, et al. Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity. *Dig Dis Sci.* 2012;57:2408–15 (**elderly \geq 65 y.o.**).
19. Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. *Clin Gastroenterol Hepatol.* 2011;9:30–5 (**elderly \geq 65 y.o.**).
20. Almogy G, Sachar DB, Bodian CA, et al. Surgery for ulcerative colitis in elderly persons: changes in indications for surgery and outcome over time. *Arch Surg. (Chicago IL 1960).* 2001;136:1396–400 (**elderly \geq 65 y.o.**).
21. Ananthakrishnan AN, McGinley EL, Binion DG. Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. *Inflamm Bowel Dis.* 2009;15:182–9 (**elderly \geq 65 y.o.**).
22. Matsumoto S, Miyatani H, Yoshida Y. Ulcerative colitis: comparison between elderly and young adult patients and between elderly patients with late-onset and long-standing disease. *Dig Dis Sci.* 2013;58:1306–12 (**elderly \geq 60 y.o.**).
23. Ouchi Y, Rakugi H, Arai H, et al. Redefining the elderly as aged 75 years and older: proposal from the Joint Committee of Japan Gerontological Society and the Japan Geriatrics Society. *Geriatr Gerontol Int.* 2017;17:1045–7 (**elderly \geq 75 y.o.**).
24. Loftus CG, Loftus EV Jr, Harmsen WS, et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. *Inflamm Bowel Dis.* 2007;13:254–61 (**no definition of elderly**).
25. Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986–2005: a KASID study. *Inflamm Bowel Dis.* 2008;14:542–9 (**no definition of elderly**).
26. Ling KL, Ooi CJ, Luman W, et al. Clinical characteristics of ulcerative colitis in Singapore, a multiracial city-state. *J Clin Gastroenterol.* 2002;35:144–8 (**no definition of elderly**).
27. Subasinghe D, Nawarathna NM, Samarasekera DN. Disease characteristics of inflammatory bowel disease (IBD): findings from a tertiary care centre in South Asia. *J Gastrointest Surg.* 2011;15:1562–7 (**no definition of elderly**).
28. Prideaux L, Kamm MA, De Cruz PP, et al. Inflammatory bowel disease in Asia: a systematic review. *J Gastroenterol Hepatol.* 2012;27:1266–80 (**review**).
29. Asakura K, Nishiwaki Y, Inoue N, et al. Prevalence of ulcerative colitis and Crohn's disease in Japan. *J Gastroenterol.* 2009;44:659–65 (**no definition of elderly**).
30. Takahashi H, Matsui T, Hisabe T, et al. Second peak in the distribution of age at onset of ulcerative colitis in relation to smoking cessation. *J Gastroenterol Hepatol.* 2014;29:1603–8 (**elderly \geq 50 y.o.**).
31. Song EM, Lee HS, Park SH, et al. Clinical characteristics and long-term prognosis of elderly onset ulcerative colitis. *J Gastroenterol Hepatol.* 2018;33:172–9 (**elderly \geq 60 y.o.**).
32. Araki M, Shinzaki S, Yamada T, et al. Age at onset is associated with the seasonal pattern of onset and exacerbation in inflammatory bowel disease. *J Gastroenterol.* 2017;52:1149–57 (**elderly > 40 y.o.**).
33. Lee KS, Shin WG, Jang MK, et al. Who are susceptible to pseudomembranous colitis among patients with presumed antibiotic-associated diarrhea? *Dis Colon Rectum.* 2006;49:1552–8 (**no definition of elderly**).
34. Nomura K, Fujimoto Y, Yamashita M, et al. Absence of pseudomembranes in *Clostridium difficile*-associated diarrhea in patients using immunosuppression agents. *Scand J Gastroenterol.* 2009;44:74–8 (**no definition of elderly**).
35. Ko JH, Peck KR, Lee WJ, et al. Clinical presentation and risk factors for cytomegalovirus colitis in immunocompetent adult patients. *Clin Infect Dis.* 2015;60:e20–6 (**no definition of elderly**).
36. Nakase H, Honzawa Y, Toyonaga T, et al. Diagnosis and treatment of ulcerative colitis with cytomegalovirus infection: importance of controlling mucosal inflammation to prevent cytomegalovirus reactivation. *Intest Res.* 2014;12:5–11 (**review**).
37. Sarin A, Safar B. Management of radiation proctitis. *Gastroenterol Clin N Am.* 2013;42:913–25 (**review**).
38. Yasuda Y, Urata Y, Tohna R, et al. Immune-related colitis induced by the long-term use of nivolumab in a patient with non-small cell lung cancer. *Intern Med.* 2018;57:1269–72 (**case report**).
39. Yamauchi R, Araki T, Mitsuyama K, et al. The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review. *BMC Gastroenterol.* 2018;18:135 (**case report**).
40. Okamoto R, Negi M, Tomii S, et al. Diagnosis and treatment of microscopic colitis. *Clin J Gastroenterol.* 2016;9:169–74 (**review**).
41. Umeno J, Esaki M, Nuki Y, et al. Letter: Lansoprazole consumption is more common in Japanese patients with collagenous colitis. *Aliment Pharmacol Ther.* 2013;38:208–9 (**no definition of elderly**).
42. Tados M, Majumder S, Birk JW. A review of ischemic colitis: is our clinical recognition and management adequate? *Expert Rev Gastroenterol Hepatol.* 2013;7:605–13 (**review**).
43. Jani N, Finkelstein S, Blumberg D, et al. Segmental colitis associated with diverticulosis. *Dig Dis Sci.* 2002;47:1175–81 (**review**).
44. Tursi A, Elisei W, Giorgetti GM, et al. Segmental colitis associated with diverticulosis: a 5-year follow-up. *Int J Colorectal Dis.* 2012;27:179–85 (**review**).
45. Cassieri C, Brandimarte G, Elisei W, et al. How to differentiate segmental colitis associated with diverticulosis and inflammatory bowel diseases. *J Clin Gastroenterol.* 2016;50(Suppl 1):S36–8 (**review**).
46. Abid S, Khawaja A, Bhimani SA, et al. The clinical, endoscopic and histological spectrum of the solitary rectal ulcer syndrome: a

- single-center experience of 116 cases. *BMC Gastroenterol.* 2012;12:72 (**no definition of elderly**).
47. Park HB, Park HC, Chung CY, et al. Coexistence of solitary rectal ulcer syndrome and ulcerative colitis: a case report and literature review. *Intest Res.* 2014;12:70–3 (**case report**).
 48. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN study). *Scand J Gastroenterol.* 2009;44:431–40 (**elderly \geq 50 y.o.**).
 49. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. *Gut.* 2001;48:526–35 (**meta-analysis**).
 50. Beauverie L, Svrcek M, Seksik P, et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. *Gastroenterology.* 2013;145:166–75 (**elderly \geq 65 y.o.**).
 51. Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. *Gastroenterology.* 2006;130:1030–8 (**no definition of elderly**).
 52. Lutgens MW, van Oijen MG, van der Heijden GJ, et al. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. *Inflamm Bowel Dis.* 2013;19:789–99 (**meta-analysis**).
 53. Brackmann S, Andersen SN, Aamodt G, et al. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease. *Scand J Gastroenterol.* 2009;44:46–55 (**no definition of elderly**).
 54. Song EM, Kim N, Lee SH, et al. Clinical characteristics and long-term prognosis of elderly-onset Crohn's disease. *Scand J Gastroenterol.* 2018;53:417–25 (**elderly \geq 60 y.o.**).
 55. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. *Gastroenterology.* 2008;134:929–36 (**oldest group \geq 50 y.o.**).
 56. Bewtra M, Newcomb CW, Wu Q, et al. Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study. *Ann Intern Med.* 2015;163:262–70 (**elderly \geq 50 y.o.**).
 57. Naganuma M, Kunisaki R, Yoshimura N, et al. A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease. *J Gastroenterol.* 2013;48:595–600 (**oldest group \geq 50 y.o.**).
 58. Kirchgessner J, Lemaître M, Carrat F, et al. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. *Gastroenterology.* 2018;155:337–46 (**elderly \geq 65 y.o.**).
 59. Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. *J Crohns Colitis.* 2014;8:443–68 (**consensus**).
 60. Naganuma M, Nagahori M, Fujii T, et al. Poor recall of prior exposure to varicella zoster, rubella, measles, or mumps in patients with IBD. *Inflamm Bowel Dis.* 2013;19:418–22 (**no definition of elderly**).
 61. Wasan SK, Baker SE, Skolnik PR, et al. A practical guide to vaccinating the inflammatory bowel disease patient. *Am J Gastroenterol.* 2010;105:1231–8 (**guideline**).
 62. Winthrop KL, Melmed GY, Vermeire S, et al. Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. *Inflamm Bowel Dis.* 2018;24:2258–65 (**elderly \geq 65 y.o.**).
 63. Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. *N Engl J Med.* 2016;375:1019–32 (**elderly \geq 70 y.o.**).
 64. Hagihara Y, Ohfuji S, Watanabe K, et al. Infliximab and/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease. *J Crohns Colitis.* 2014;8:223–33 (**oldest group \geq 49 y.o.**).
 65. Matsumoto H, Ohfuji S, Watanabe K, et al. Booster influenza vaccination does not improve immune response in adult inflammatory bowel disease patients treated with immunosuppressives: a randomized controlled trial. *J Gastroenterol.* 2015;50:876–86 (**no definition of elderly**).
 66. Weismuller TJ, Trivedi PJ, Bergquist A, et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. *Gastroenterology.* 2017;152:1975–84 (**no definition of elderly**).
 67. Kaplan GG, Hubbard J, Panaccione R, et al. Risk of comorbidities on postoperative outcomes in patients with inflammatory bowel disease. *Arch Surg.* 2011;146:959–64 (**meta-analysis**).
 68. Ananthakrishnan AN, McGinley EL. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. *J Crohns Colitis.* 2013;7:107–12 (**elderly $>$ 65 y.o.**).
 69. Brassard P, Bitton A, Suissa A, et al. Oral corticosteroids and the risk of serious infections in patients with elderly-onset inflammatory bowel diseases. *Am J Gastroenterol.* 2014;109:1795–802 (**elderly \geq 66 y.o.**).
 70. Das R, Feuerstadt P, Brandt LJ. Glucocorticoids are associated with increased risk of short-term mortality in hospitalized patients with *Clostridium difficile*-associated disease. *Am J Gastroenterol.* 2010;105:2040–9 (**no definition of elderly**).
 71. Nguyen GC, Kaplan GG, Harris ML, et al. A national survey of the prevalence and impact of *Clostridium difficile* infection among hospitalized inflammatory bowel disease patients. *Am J Gastroenterol.* 2008;103:1443–50 (**no definition of elderly**).
 72. Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. *Clin Gastroenterol Hepatol.* 2006;4:1483–90 (**elderly \geq 65 y.o.**).
 73. Tsai SY, Yang TY, Lin CL, et al. Increased risk of varicella zoster virus infection in inflammatory bowel disease in an Asian population: a nationwide population-based cohort study. *Int J Clin Pract.* 2015;69:228–34 (**elderly \geq 65 y.o.**).
 74. Yajnik V, Khan N, Dubinsky M, et al. Efficacy and safety of vedolizumab in ulcerative colitis and Crohn's disease patients stratified by age. *Adv Ther.* 2017;34:542–59 (**elderly \geq 55 y.o.**).
 75. Kishikawa J, Hata K, Kazama S, et al. Results of a 36-year surveillance program for ulcerative colitis-associated neoplasia in the Japanese population. *Dig Endosc.* 2018;30:236–44 (**no definition of elderly**).
 76. Nimmons D, Limdi JK. Elderly patients and inflammatory bowel disease. *World J Gastrointest Pharmacol Ther.* 2016;7:51–65 (**review**).
 77. Tran AH, Man Ngor EW, Wu BU. Surveillance colonoscopy in elderly patients: a retrospective cohort study. *JAMA Intern Med.* 2014;174:1675–82 (**elderly \geq 75 y.o.**).
 78. Stepaniuk P, Bernstein CN, Targownik LE, et al. Characterization of inflammatory bowel disease in elderly patients: a review of epidemiology, current practices and outcomes of current management strategies. *Can J Gastroenterol Hepatol.* 2015;29:327–33 (**review**).
 79. Verstockt B, Ferrante M, Vermeire S, et al. New treatment options for inflammatory bowel diseases. *J Gastroenterol.* 2018;53:585–90 (**review**).
 80. Baggenstos BR, Hanson BJ, Shaukat A. Treatment of ulcerative colitis in the elderly: a systematic review. *Clin Med Insights Geriatr.* 2013;6:1–26 (**elderly \geq 60 y.o.**).
 81. Ananthakrishnan AN, Donaldson T, Lasch K, et al. Management of inflammatory bowel disease in the elderly patient: challenges

- and opportunities. *Inflamm Bowel Dis.* 2017;23:882–93 (**review**).
82. Lobaton T, Ferrante M, Rutgeerts P, et al. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. *Aliment Pharmacol Ther.* 2015;42:441–51 (**elderly \geq 65 y.o.**).
 83. Desai A, Zator ZA, de Silva P, et al. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. *Inflamm Bowel Dis.* 2013;19:309–15 (**elderly > 60 y.o.**).
 84. Ito A, Omori T, Hanafusa N, et al. Efficacy and safety of granulocyte adsorption apheresis in elderly patients with ulcerative colitis. *J Clin Apheresis.* 2018;33:514–20 (**elderly \geq 65 y.o.**).
 85. Yamamoto T, Iida T, Ikeya K, et al. A multicenter retrospective study aiming to identify patients who respond well to adsorptive granulomonocytapheresis in moderately to severely active ulcerative colitis. *Clin Transl Gastroenterol.* 2018;9:170 (**elderly > 60 y.o.**).
 86. Kawamura H, Matsumoto S, Nakamura N, et al. Rapid induction therapy with oral tacrolimus in elderly patients with refractory ulcerative colitis can easily lead to elevated tacrolimus concentrations in blood: a report of 5 cases. *Am J Case Rep.* 2017;18:405–9 (**elderly \geq 65 y.o.**).
 87. Kobayashi R, Matsumoto S, Yoshida Y. Tacrolimus therapy for three patients with elderly-onset ulcerative colitis: report of three cases. *Case Rep Gastroenterol.* 2016;10:392–8 (**elderly \geq 60 y.o.**).
 88. Full prescribing information (XELJANZ/XELJANZ XR): Pfizer Labs. <http://www.pmda.go.jp/drugs/2018/P20180620001/index.html>. Accessed 26 Mar 2019 (**elderly \geq 65 y.o.**).
 89. Stallmach A, Hagel S, Gharbi A, et al. Medical and surgical therapy of inflammatory bowel disease in the elderly—prospects and complications. *J Crohns Colitis.* 2011;5:177–88 (**review, elderly \geq 65 y.o.**).
 90. Long MD, Kappelman MD, Martin CF, et al. Risk factors for depression in the elderly inflammatory bowel disease population. *J Crohns Colitis.* 2014;8:113–9 (**elderly \geq 65 y.o.**).
 91. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. *Arch Intern Med.* 2005;165:1095–106 (**review**).
 92. Vazquez SR, Rondina MT, Pendleton RC. Azathioprine-induced warfarin resistance. *Ann Pharmacother.* 2008;42:1118–23 (**no definition of elderly**).
 93. Katz S, Pardi DS. Inflammatory bowel disease of the elderly: frequently asked questions (FAQs). *Am J Gastroenterol.* 2011;106:1889–97 (**review**).
 94. Lowry PW, Franklin CL, Weaver AL, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. *Gut.* 2001;49:656–64 (**no definition of elderly**).
 95. Akerkar GA, Peppercorn MA, Hamel MB, et al. Corticosteroid-associated complications in elderly Crohn's disease patients. *Am J Gastroenterol.* 1997;92:461–4 (**meta-analysis, elderly \geq 50 y.o.**).
 96. Vinod J, Vadada D, Korelitz BI, et al. The effect of antiplatelet therapy in patients with inflammatory bowel disease. *J Clin Gastroenterol.* 2012;46:527–9 (**no definition of elderly**).
 97. Danese S, De La Motte C, Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. *Am J Gastroenterol.* 2004;99:938–45 (**review**).
 98. Tan VP, Chung A, Yan BP, et al. Venous and arterial disease in inflammatory bowel disease. *J Gastroenterol Hepatol.* 2013;28:1095–113 (**meta-analysis**).
 99. Timmer A, Patton PH, Chande N, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. *Cochrane Database Syst Rev.* 2016;(5):CD000478 (**meta-analysis**).
 100. Hibi T, Naganuma M, Kitahora T, et al. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. *J Gastroenterol.* 2003;38:740–6 (**no definition of elderly**).
 101. Alexakis C, Saxena S, Chhaya V, et al. Do thiopurines reduce the risk of surgery in elderly onset inflammatory bowel disease? A 20-year national population-based cohort study. *Inflamm Bowel Dis.* 2017;23:672–80 (**elderly > 60 y.o.**).
 102. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. *Gastroenterology.* 2014;146:392–400 (**elderly \geq 65 y.o.**).
 103. Manosa M, Calafat M, de Francisco R, et al. Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study. *Aliment Pharmacol Ther.* 2018;47:605–14 (**elderly \geq 60 y.o.**).
 104. Aberna FN, Stettler N, Brensinger C, et al. Risk for active tuberculosis in inflammatory bowel disease patients. *Clin Gastroenterol Hepatol.* 2007;5:1070–5 (**no definition of elderly**).
 105. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. *Gut.* 2005;54:1121–5 (**oldest group \geq 70 y.o.**).
 106. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. *Lancet.* 2009;374:1617–25 (**elderly > 65 y.o.**).
 107. Subramaniam K, D'Rozario J, Pavli P. Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review. *J Gastroenterol Hepatol.* 2013;28:24–30 (**review**).
 108. Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. *Clin Gastroenterol Hepatol.* 2015;13:847–58 (**meta-analysis, oldest group \geq 70 y.o.**).
 109. Lemaitre M, Kirchgessner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. *JAMA.* 2017;318:1679–86 (**oldest group \geq 65 y.o.**).
 110. Fukata N, Okazaki K, Omiya M, et al. Hematologic malignancies in the Japanese patients with inflammatory bowel disease. *J Gastroenterol.* 2014;49:1299–306 (**no definition of elderly**).
 111. Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. *Gastroenterology.* 2012;143:390–99 (**no definition of elderly**).
 112. Moran GW, Lim AW, Bailey JL, et al. Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease. *Aliment Pharmacol Ther.* 2013;38:1002–24 (**review**).
 113. Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a *Streptomyces*. II. Immunosuppressive effect of FK-506 in vitro. *J Antibiot.* 1987;40:1256–65 (**no definition of elderly**).
 114. Kelly P, Kahan BD. Review: metabolism of immunosuppressant drugs. *Curr Drug Metab.* 2002;3:275–87 (**review**).
 115. Kawai S, Yamamoto K. Safety of tacrolimus, an immunosuppressive agent, in the treatment of rheumatoid arthritis in elderly patients. *Rheumatology (Oxford).* 2006;45:441–4 (**elderly \geq 65 y.o.**).
 116. Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of

- ulcerative colitis. Part 2: current management. *J Crohns Colitis*. 2017;11:769–84 (**review**).
117. Komaki Y, Komaki F, Ido A, et al. Efficacy and safety of tacrolimus therapy for active ulcerative colitis; a systematic review and meta-analysis. *J Crohns Colitis*. 2016;10:484–94 (**meta-analysis**).
 118. Baumgart DC, Pintoff JP, Sturm A, et al. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease—a long-term follow-up. *Am J Gastroenterol*. 2006;101:1048–56 (**no definition of elderly**).
 119. Escher M, Stange EF, Herrlinger KR. Two cases of fatal *Pneumocystis jirovecii* pneumonia as a complication of tacrolimus therapy in ulcerative colitis—a need for prophylaxis. *J Crohns Colitis*. 2010;4:606–9 (**no definition of elderly**).
 120. Taleban S, Colombel JF, Mohler MJ, et al. Inflammatory bowel disease and the elderly: a review. *J Crohns Colitis*. 2015;9:507–15 (**review, elderly ≥ 60 y.o.**).
 121. Pardi DS, Loftus EV Jr, Camilleri M. Treatment of inflammatory bowel disease in the elderly: an update. *Drugs Aging*. 2002;19:355–63 (**review**).
 122. Benchimol EI, Cook SF, Erichsen R, et al. International variation in medication prescription rates among elderly patients with inflammatory bowel disease. *J Crohns Colitis*. 2013;7:878–89 (**elderly ≥ 65 y.o.**).
 123. Kornbluth A, Present DH, Lichtiger S, et al. Cyclosporin for severe ulcerative colitis: a user's guide. *Am J Gastroenterol*. 1997;92:1424–8 (**guideline**).
 124. Staatz CE, Tett SE. Pharmacokinetic considerations relating to tacrolimus dosing in the elderly. *Drugs Aging*. 2005;22:541–57 (**review**).
 125. Gentil MA, Osuna A, Capdevila L, et al. Safety and efficacy of delayed introduction of low-dose tacrolimus in elderly recipients of cadaveric renal transplants from donors over 55 years of age. *Transplant Proc*. 2003;35:1706–8 (**elderly > 50 y.o.**).
 126. Takeuchi T, Kawai S, Yamamoto K, et al. Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3,267 Japanese patients with rheumatoid arthritis. *Mod Rheumatol*. 2014;24:8–16 (**elderly ≥ 65 y.o.**).
 127. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. *J Crohns Colitis*. 2009;3:47–91 (**review**).
 128. Bernstein CN, Blanchard JF, Kliever E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. *Cancer*. 2001;91:854–62 (**oldest group ≥ 60 y.o.**).
 129. Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. *Gastroenterology*. 2001;121:1080–7 (**no definition of elderly**).
 130. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. *Gut*. 2009;58:501–8 (**elderly ≥ 60 y.o.**).
 131. Colombel J-F, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. *Gastroenterology*. 2004;126:19–31 (**no definition of elderly**).
 132. Khanna D, McMahon M, Furst DE. Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here? *Arthritis Rheum*. 2004;50:1040–50 (**review**).
 133. Komoto S, Matsuoka K, Kobayashi T, et al. Safety and efficacy of leukocytapheresis in elderly patients with ulcerative colitis: the impact in steroid-free elderly patients. *J Gastroenterol Hepatol*. 2018;33:1485–91 (**elderly ≥ 65 y.o.**).
 134. Futatsuki R, Kuroki H, Sugita A, et al. Clinical analysis of the postoperative bowel function in elderly patients with ulcerative colitis. *Jpn J Gastroenterol Surg*. 2016;49:714–20 (**elderly ≥ 65 y.o.**).
 135. Sugita A, Koganei K, Tatsumi K, et al. Recent advances in medical and surgical treatment of ulcerative colitis. *Nihon Geka Gakkai zasshi*. 2015;116:99–103 (**no definition of elderly**).
 136. del Val JH. Old-age inflammatory bowel disease onset: a different problem? *World J Gastroenterol*. 2011;17:2734–9 (**review**).
 137. Delaney CP, Dadvand B, Remzi FH, et al. Functional outcome, quality of life, and complications after ileal pouch-anal anastomosis in selected septuagenarians. *Dis Colon Rectum*. 2002;45:890–4 (**elderly ≥ 70 y.o.**).
 138. Delaney CP, Fazio VW, Remzi FH, et al. Prospective, age-related analysis of surgical results, functional outcome, and quality of life after ileal pouch-anal anastomosis. *Ann Surg*. 2003;238:221–8 (**oldest group > 65 y.o.**).
 139. Chapman JR, Larson DW, Wolff BG, et al. Ileal pouch-anal anastomosis: does age at the time of surgery affect outcome? *Arch Surg*. 2005;140:534–9 (**oldest group > 55 y.o.**).
 140. Watanabe K, Nagao M, Suzuki H, et al. The functional outcome and factors influencing the quality of life after ileal pouch anal anastomosis in patients with ulcerative colitis. *Surg Today*. 2018;48:455–61 (**older group ≥ 45 y.o.**).
 141. Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. *J Crohns Colitis*. 2017;11:649–70 (**consensus**).
 142. Dayton MT, Larsen KR. Should older patients undergo ileal pouch-anal anastomosis? *Am J Surg*. 1996;172:444–7 (**older group > 55 y.o.**).
 143. Longo WE, Virgo KS, Bahadursingh AN, et al. Patterns of disease and surgical treatment among United States veterans more than 50 years of age with ulcerative colitis. *Am J Surg*. 2003;186:514–8 (**oldest group ≥ 70 y.o.**).
 144. Kohn RR. Human aging and disease. *J Chronic Dis*. 1963;16:5–21 (**review**).
 145. McKenna NP, Mathis KL, Pemberton JH, et al. The impact of age at time of ileal pouch anal anastomosis on short and long-term outcomes in adults. *Inflamm Bowel Dis*. 2018;24:1857–65 (**older group > 50 y.o.**).
 146. Ramage L, Qiu S, Georgiou P, et al. Functional outcomes following ileal pouch-anal anastomosis (IPAA) in older patients: a systematic review. *Int J Colorectal Dis*. 2016;31:481–92 (**meta-analysis, elderly ≥ 65 ± 5 y.o.**).
 147. Lightner AL, Mathis KL, Dozois EJ, et al. Results at up to 30 years after ileal pouch-anal anastomosis for chronic ulcerative colitis. *Inflamm Bowel Dis*. 2017;23:781–90 (**elderly ≥ 65 y.o.**).
 148. Tan KK, Manoharan R, Rajendran S, et al. Assessment of age in ulcerative colitis patients with ileal pouch creation—an evaluation of outcomes. *Ann Acad Med Singap*. 2015;44:92–7 (**older group > 50 y.o.**).
 149. Kim H, Sun L, Gurland B, et al. Does stool leakage increase in aging pouches? *Dis Colon Rectum*. 2015;58:1158–63 (**no definition of elderly**).
 150. Stryker SJ, Pemberton JH, Zinsmeister AR. Long-term results of ileostomy in older patients. *Dis Colon Rectum*. 1985;28:844–6 (**elderly ≥ 60 y.o.**).

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.